MLYS

ANALYST NOTE: MINERALYS THERAPEUTICS, INC. (MLYS) DATE: 2026-06-13 SUBJECT: Structural Setup Analysis & Business Fundamentals

1. Structural Readiness

Current State: INVALIDATED

• Current Price: $24.63
• Breakout Level (Resistance): $47.65
• Aggressive Entry (Pre-breakout): $30.01 (Note: This entry is no longer viable as the structure has broken down).
• Conservative Entry: None (Setup is invalidated).
• Extension: —

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Exposure: None named at this date.

As of June 13, 2026, MLYS is not anchored to a named macro or secular thesis in the current data set. It is a tactical, setup-led name. Consequently, conviction must be derived strictly from the quality of the technical structure (which is currently broken) and the underlying business fundamentals. No external thematic tailwinds (e.g., specific regulatory shifts or sector-wide M&A) are currently cited to override the structural invalidation. The analysis must remain grounded in the binary nature of the NDA approval timeline and the company's cash runway, rather than speculative secular growth narratives.

3. Business Fundamentals

Company Overview: Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Radnor, Pennsylvania, established in 2019. The company is developing lorundrostat, a selective aldosterone synthase inhibitor (ASI).

Business Model & Pipeline: The company operates on a "high-risk, high-reward" biotech model, focusing on the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).

• Product: Lorundrostat is designed to treat hypertension in combination with other antihypertensive drugs.
• Target Population: The company targets the ~20 million patients in the US with uncontrolled hypertension and the ~10 million with resistant hypertension (defined as failure to achieve BP goals despite 3+ medications).
• Clinical Data: As of the Q1 2026 earnings transcript (May 6, 2026), the company has completed six clinical trials supporting lorundrostat. Key trials include:
• Launch-HTN: A Phase 3 trial meeting endpoints with statistically significant reductions in systolic BP.
• Advance-HTN, Transform-HTN, Target-HTN, Explore-CKD: Supporting efficacy and safety profiles.
• Mechanism: Dysregulated aldosterone is identified as a key factor in ~30% of uHTN/rHTN patients.

Regulatory Status (As of June 13, 2026):

• NDA Submission: The company submitted its New Drug Application (NDA) to the FDA in December 2025.
• FDA Acceptance: The FDA accepted the NDA and assigned a PDUFA target date of December 22, 2026.
• Management Expectation: Management stated in May 2026 that operational focus is shifting to "preparing lorundrostat for commercial success" as the PDUFA date approaches.

Financial Position (As of March 31, 2026):

• Cash Position: $646.1 million in cash, cash equivalents, and investments.
• Runway: Management expects these funds to be sufficient to fund operations and clinical/regulatory activities into 2028.
• R&D Spend: R&D expenses for Q1 2026 were $24.4 million, down from $37.9 million in the prior year quarter, indicating a shift toward cost efficiency as the company nears commercialization.
• Liabilities: Accumulated deficit of $496.5 million.
• Commercial Milestones: Remaining obligations to partner Tanabe include up to $155.0 million in commercial milestones upon first sale and sales targets, plus $10.0 million for a second indication.

4. Archetype and Conviction

Archetype: Growth Leader (Pre-Commercial)

• Fit: The company fits the "Growth Leader" archetype due to its position at the cusp of commercialization for a novel mechanism of action in a large, unmet medical need market. The "Growth" narrative is entirely dependent on the successful regulatory approval of lorundrostat.
• Valuation Context: The financial spine indicates forward consensus EPS of -2.31 (FY1) and -2.09 (FY2). The company is pre-revenue, with valuation driven by the probability of approval and future commercial potential rather than current earnings.
• Conviction Stack:
• Thesis Strength: Low (No named secular thesis; purely binary event-driven).
• Evidence Quality: High. The clinical data package is comprehensive (6 trials), and the NDA acceptance is a confirmed regulatory milestone.
• Structural Quality: Poor. The setup is invalidated. The "Very High" ATR (6.4%) suggests the market is pricing in significant uncertainty or negative sentiment regarding the near-term path to the December PDUFA date.
• Rerating Potential: High *if* the PDUFA is approved, but currently suppressed by the structural breakdown and the 6-month wait to the decision date.

Summary: While the business fundamentals (cash runway, clinical data, regulatory acceptance) are strong, the technical structure is currently broken. The "Growth Leader" potential is real, but the entry signal is absent. The setup requires a reformation above $25.64 to be considered active again.

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate the Case Further:

• FDA Delay or Refusal: Any news prior to December 22, 2026, indicating a delay in the PDUFA review or a request for additional data would be catastrophic given the current price sensitivity.
• Cash Burn Acceleration: If R&D or commercialization costs spike significantly before the PDUFA date, threatening the "funding into 2028" runway.

What Would Strengthen the Case:

• FDA Advisory Committee Positive Vote: A positive recommendation from the FDA advisory committee prior to the PDUFA date would likely trigger a reformation of the coil structure.
• Commercial Partnership: Announcement of a new commercialization partner or licensing deal (beyond the existing Tanabe agreement) to share risk.

Evidence Gaps:

• Pricing/Reimbursement Details: While management notes payers are "willing to provide coverage," specific pricing data or reimbursement rates are not detailed in the provided evidence.
• Commercialization Costs: The specific cost to build the sales force and distribution network for lorundrostat is not quantified in the provided filings, only the R&D spend.
• Competitive Landscape: No specific data on competing therapies in the resistant hypertension space is provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Sell Confidence: high Key risks: FDA PDUFA decision in December 2026 remains a binary event with 6 months of uncertainty; High cash burn relative to pre-revenue status despite current runway; Lack of named secular thesis to support holding through volatility. Sizing hint: Position size should be zero; capital is better deployed in setups with confirmed active structures. Expected path: Management expects to fund operations into 2028 and prepare for commercial launch post-December 2026; price likely to remain range-bound or decline until a catalyst (PDUFA decision) or structural reformation occurs. Expected horizon: 6 months (until PDUFA decision) or indefinite until technical structure repairs. Failure mode to watch: A sustained close below $25.64 confirms the invalidation; any further drop below recent lows would signal continued structural failure.